Keywords:
BRAF; FIREFLY-1; optic pathway glioma; tovorafenib; visual acuity; neoplasms; pediatrics
Abstract:
Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.